Search for Stocks /

Shaily Engineering Plastics Ltd Q3 FY26: 96% PAT Jump, 27% OPM, ₹236 Cr Quarter — But Trading at 66x Earnings. Genius Growth or Glorious Overconfidence?


1. At a Glance – The Plastic Surgeon of Pharma Devices Is Minting Margins

₹9,446 crore market cap. ₹2,055 stock price. 66.4 P/E. 26.6% OPM. 96.5% quarterly profit growth.

And yet the stock is down 20.8% in the last 3 months.

Ladies and gentlemen, welcome to the paradox of Shaily Engineering Plastics Ltd — a precision injection-moulding specialist quietly riding the GLP-1 injection wave while the market debates whether it deserves a superstar valuation.

December 2025 quarter delivered ₹236 crore in sales and ₹35.6 crore PAT. That’s a 26.9% revenue growth and a dramatic 96.5% jump in profit YoY. OPM touched 27%. ROCE stands at 17%. ROE at 15.3%.

But here’s the spicy bit — the stock trades at 16.7 times book value.

So the big question:
Is this a future medical-device powerhouse in the making… or is the market already pricing in a flawless future?

Grab your plastic syringe. We are going deep.


2. Introduction – From Toys to GLP-1 Pens, This Escalated Quickly

Once upon a time, Shaily was making plastic components for consumer goods. FMCG packaging. Home furnishings. Toys.

Then pharma devices entered the chat.

And suddenly, this wasn’t just a plastic moulder — this became a pen-injector capacity expansion story.

Today:

  • 78.6% revenue from exports
  • 17.1% revenue from healthcare
  • Signed 6 contracts for GLP-1 and other therapy pen injectors
  • Planning ₹100 crore capex in FY26
  • Sequential capacity jump from ~45 million to ~85 million pen devices

That’s not small ambition.

They’re even building two 80-parts-per-minute lines targeting 50–60 million extra units by December 2026.

Let me ask you something:

When a company moves from LED housings to medical injectors…
Do margins change?
Do valuations change?
Do risks change?

Exactly.

Let’s decode.


3. Business Model – WTF Do They Even Do?

Shaily is a precision plastic injection moulding specialist.

Translation:
They don’t sell branded products. They manufacture complex plastic components and sub-assemblies for OEMs.

Three segments:

1️ Consumer (74.3% of 9MFY25 revenue)

  • Home furnishing components
  • FMCG packaging
  • LED light parts
  • Toys (via partnership with Spin Master)
  • Two global retail chains onboarding from FY26

This is bread-and-butter revenue. Stable. Export-heavy.

2️ Healthcare (17.1%)

This is where the future is hiding.

Products:

  • Pen Injectors
  • Auto-injectors
  • Wearable injectors
  • Pharma packaging
  • Platform devices

GLP-1 therapy pens are the hot global trend.

If weight-loss drugs are the “Netflix

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →